Home

Concurrent Analytical is a diagnostic research and development company and is the inventor of Ramanprobes.  Ramanprobes is a revolutionary new method in point-of-care diagnostics that enables the possibility to detect and identify multiple cancer biomarkers concurrently in seconds, at the sensitivity and specificity necessary for early cancer diagnosis. 

Only a drop of blood is necessary for the analysis.

Ramanprobes has been used successfully in the early detection of pancreatic cancer. So early in fact that for the first time, therapy for pancreatic cancer may be possible.  Ramanprobes  can be used for most cancers where biomarkers have been identified, and for virus detection.  Concurrent Analytical Inc. has been recently chosen by NSF to develop its Ramanprobes system to battle the Herpes virus epidemic.  Read about it here.

It is our vision and goal that when combined with the ongoing industry effort using proteomics to identify cancer biomarkers, Ramanprobes will be the diagnostic method of choice to profile those biomarkers.  Ramanprobes has the ability to provide the detection and identification of cancer through biomarkers at an earlier stage then by other methods - thereby affording the best chance of recovery. 

This is the beginning in a new paradigm of diagnostics - we call it Advanced Wellness Testing. 

Visit our technology spin-off divisions at: